{"id":"https://openalex.org/W9899198","doi":"https://doi.org/10.1182/blood.v122.21.690.690","title":"Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma","display_name":"Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W9899198","doi":"https://doi.org/10.1182/blood.v122.21.690.690","mag":"9899198"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.690.690","doi":"https://doi.org/10.1182/blood.v122.21.690.690","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.690.690","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108104588","display_name":"Jatin J. Shah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jatin J. Shah","raw_affiliation_strings":["Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center, Houston , TX , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center, Houston , TX , USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029801761","display_name":"Edward Allen Stadtmauer","orcid":"https://orcid.org/0000-0002-3935-6069","observed_orcids":["https://orcid.org/0000-0002-3935-6069"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Edward A. Stadtmauer","raw_affiliation_strings":["Hematologic Malignancies Program, Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematologic Malignancies Program, Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA, USA,","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047486042","display_name":"Rafat Abonour","orcid":"https://orcid.org/0000-0003-1491-2548","observed_orcids":["https://orcid.org/0000-0003-1491-2548"]},"institutions":[{"id":"https://openalex.org/I4388446366","display_name":"Indiana University Indianapolis","ror":"https://ror.org/03eftgw80","country_code":"US","type":"education","lineage":["https://openalex.org/I4388446366","https://openalex.org/I592451"]},{"id":"https://openalex.org/I4394709130","display_name":"Indiana University School of Medicine","ror":"https://ror.org/02ets8c94","country_code":"US","type":"education","lineage":["https://openalex.org/I4394709130","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rafat Abonour","raw_affiliation_strings":["Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA,","institution_ids":["https://openalex.org/I4388446366","https://openalex.org/I4394709130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025168585","display_name":"Adam D. Cohen","orcid":"https://orcid.org/0000-0003-0939-3843","observed_orcids":["https://orcid.org/0000-0003-0939-3843"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Adam D. Cohen","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, PA, USA,","Fox Chase Cancer Center,#R#Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, PA, USA,","institution_ids":["https://openalex.org/I1289437631"]},{"raw_affiliation_string":"Fox Chase Cancer Center,#R#Philadelphia, PA, USA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113514827","display_name":"William Bensinger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"William Bensinger","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center , Seattle, WA , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center , Seattle, WA , USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033550793","display_name":"Cristina Gasparetto","orcid":"https://orcid.org/0000-0003-1513-5605","observed_orcids":["https://orcid.org/0000-0003-1513-5605"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cristina Gasparetto","raw_affiliation_strings":["Duke University Medical Center, Durham, NC, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC, USA,","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077897003","display_name":"Jonathan L. Kaufman","orcid":"https://orcid.org/0000-0002-5687-6429","observed_orcids":["https://orcid.org/0000-0002-5687-6429"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan L. Kaufman","raw_affiliation_strings":["Winship Cancer Institute, Emory University, Atlanta, GA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute, Emory University, Atlanta, GA, USA,","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031344736","display_name":"Suzanne Lentzsch","orcid":"https://orcid.org/0000-0003-1708-7344","observed_orcids":["https://orcid.org/0000-0003-1708-7344"]},"institutions":[{"id":"https://openalex.org/I78577930","display_name":"Columbia University","ror":"https://ror.org/00hj8s172","country_code":"US","type":"education","lineage":["https://openalex.org/I78577930"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Suzanne Lentzsch","raw_affiliation_strings":["Department of Medicine, Columbia University, New York, NY, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Columbia University, New York, NY, USA,","institution_ids":["https://openalex.org/I78577930"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041561013","display_name":"Dan T. Vogl","orcid":"https://orcid.org/0000-0002-2935-2566","observed_orcids":["https://orcid.org/0000-0002-2935-2566"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dan T. Vogl","raw_affiliation_strings":["Multiple Myeloma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multiple Myeloma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA,","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038235561","display_name":"Robert Zygmunt Orlowski","orcid":"https://orcid.org/0000-0002-5723-4129","observed_orcids":["https://orcid.org/0000-0002-5723-4129"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Z. Orlowski","raw_affiliation_strings":["Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center, Houston , TX , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center, Houston , TX , USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010784610","display_name":"Erica L. Kim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267863","display_name":"Criterium, Inc. (United States)","ror":"https://ror.org/04s522687","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267863"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Erica L. Kim","raw_affiliation_strings":["Academic Myeloma Consortium (AMyC)/Criterium, Inc., Los Angeles, CA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Academic Myeloma Consortium (AMyC)/Criterium, Inc., Los Angeles, CA, USA,","institution_ids":["https://openalex.org/I4405267863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051316723","display_name":"Natalia Bialas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267863","display_name":"Criterium, Inc. (United States)","ror":"https://ror.org/04s522687","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267863"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Natalia Bialas","raw_affiliation_strings":["Criterium, Inc., Saratoga Springs, NY, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Criterium, Inc., Saratoga Springs, NY, USA,","institution_ids":["https://openalex.org/I4405267863"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086123605","display_name":"David D. Smith","orcid":"https://orcid.org/0000-0001-9644-2353","observed_orcids":["https://orcid.org/0000-0001-9644-2353"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David D. Smith","raw_affiliation_strings":["Division of Biostatistics, City of Hope, Duarte, CA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Biostatistics, City of Hope, Duarte, CA, USA,","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026109406","display_name":"Brian G.M. Durie","orcid":"https://orcid.org/0000-0002-9883-3769","observed_orcids":["https://orcid.org/0000-0002-9883-3769"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian GM Durie","raw_affiliation_strings":["Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I1282927834"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":15,"corresponding_author_ids":["https://openalex.org/A5010784610","https://openalex.org/A5025168585","https://openalex.org/A5029801761","https://openalex.org/A5031344736","https://openalex.org/A5051316723","https://openalex.org/A5086123605","https://openalex.org/A5113514827"],"corresponding_institution_ids":["https://openalex.org/I1289437631","https://openalex.org/I1301076528","https://openalex.org/I4210089486","https://openalex.org/I4210110459","https://openalex.org/I4405267863","https://openalex.org/I78577930","https://openalex.org/I79576946"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":7.8908,"has_fulltext":false,"cited_by_count":38,"citation_normalized_percentile":{"value":0.97644681,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"122","issue":"21","first_page":"690","last_page":"690"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":0.9459999799728394},{"id":"https://openalex.org/keywords/pomalidomide","display_name":"pomalidomide","score":1.0},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9879999756813049},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.906000018119812},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.8709999918937683},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6620000004768372},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8339999914169312},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9380000233650208},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.843999981880188},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9610000252723694},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.6039999723434448},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6520000100135803}],"concepts":[{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.9836517572402954},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.9682170748710632},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.8459068536758423},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6681340336799622},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6371505260467529},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.5987393260002136},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.585460901260376},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5554799437522888},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5242160558700562},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49915194511413574},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.468110054731369},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.464815229177475},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44229018688201904},{"id":"https://openalex.org/C2781098529","wikidata":"https://www.wikidata.org/wiki/Q20948663","display_name":"Ixazomib","level":5,"score":0.4392521381378174},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4143317639827728},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2396077811717987},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08077514171600342},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.690.690","doi":"https://doi.org/10.1182/blood.v122.21.690.690","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.690.690","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.7900000214576721,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2574929711","https://openalex.org/W2759274067","https://openalex.org/W2510334722","https://openalex.org/W2607267898","https://openalex.org/W2511905967","https://openalex.org/W2464924193","https://openalex.org/W2980757415","https://openalex.org/W3214193787","https://openalex.org/W282179204","https://openalex.org/W4206651001"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Carfilzomib,":[2],"a":[3,92,308,343,364,437,476,522,585,592,602,607,619,629],"novel":[4],"proteasome":[5],"inhibitor":[6],"(PI),":[7],"and":[8,35,41,48,56,65,184,204,233,235,247,422,446,461,464,471,513,521,545,559,563,567,591,605,663],"pomalidomide,":[9],"an":[10,334,517,678,693,708,727,770,786,797,810,858,872,890,904,922,934,945],"IMiD\u00ae":[11],"immunomodulatory":[12],"agent,":[13],"have":[14,43,186,486,639],"both":[15,202],"demonstrated":[16],"efficacy":[17],"as":[18,319],"single":[19],"agents":[20],"or":[21,188,237,578,683,698,713,732,775,791,802,815,863,877,895,909,927,939,950],"in":[22,26,37,74,102,137,363,496,532,618,642],"combination":[23,38],"with":[24,39,58,85,139,371,455,459,468,576,624,628,644,651],"dexamethasone":[25,59,90,239,272,329],"relapsed/refractory":[27],"multiple":[28,491],"myeloma(RRMM).":[29],"IMiD":[30],"compound+PI":[31],"combinations":[32],"including":[33,556],"lenalidomide/dex":[34],"thalidomide/dex":[36],"bortezomib":[40,626],"carfilzomib,":[42],"had":[44,177,199,436,443,584],"high":[45,608],"response":[46,156,494,609],"rates":[47],"good":[49],"tolerability.":[50],"We":[51,332,655],"aimed":[52],"to":[53,152,163,172,178,181,191,200,267,430,658],"combine":[54],"carfilzomib":[55,83,222],"pomalidomide":[57,203,214,327],"(Car-Pom-d)":[60],"for":[61,255,342,386,516,571,666],"the":[62,78,123,130,147,154,269,292,300,306,320,380,572],"first":[63,131],"time":[64,162,171,416],"hypothesized":[66],"that":[67],"this":[68,670],"regimen":[69,600,604],"would":[70,656],"be":[71,179,201],"highly":[72],"effective":[73],"patients":[75,138,176,198,312,339,348,361,377,435,454,458,466,485,501,535,551,643],"RRMM.":[76],"In":[77,299,352],"Phase":[79,125,196,301,353],"I,":[80],"dose-escalation":[81,303],"of":[82,129,135,146,209,212,271,305,310,337,345,358,368,379,408,434,478,499,519,525,534,550,588,595,612,616,631,634,669,681,696,711,730,773,789,800,813,861,875,893,907,925,937,948],"started":[84],"27mg/m2":[86,110],"carfilzomib/4mg":[87],"pomalidomide/40":[88,113],"mg":[89,114,241],"using":[91],"standard":[93],"3+3":[94],"schema":[95],"based":[96,276],"on":[97,217,226,242,277,677,692,707,726,769,785,796,809,857,871,889,903,921,933,944],"dose-limiting":[98],"toxicities":[99],"(DLTs)":[100],"occurring":[101,531],"cycle":[103],"1.":[104],"The":[105,143,315,394,405,598,883],"MTD":[106,316,341],"presented":[107],"previously":[108],"was":[109,151,250,289,317,390,397,411,419,425],"Carfilzomib":[111,205,249],"/4mg":[112],"dexamethasone.":[115],"Here,":[116],"we":[117,355,638],"report":[118],"our":[119],"combined":[120],"findings":[121],"from":[122,349,417,489],"additional":[124],"II":[126,149,197,354],"expansion":[127,335],"cohort":[128,336],"phase":[132,148],"I/II":[133],"trial":[134,307],"Car-Pom-d":[136,599],"RRMM":[140],"(NCT01464034).":[141],"Methods":[142],"primary":[144],"objective":[145],"portion":[150,304],"determine":[153],"overall":[155,168],"rate":[157,524,594,610,615],"(ORR).":[158],"Secondary":[159],"objectives":[160],"included":[161,452,536],"progression(TTP),":[164],"progression":[165],"free":[166],"survival(PFS),":[167],"survival":[169],"(OS)and":[170],"next":[173],"therapy.":[174,195,636],"All":[175],"refractory":[180,190],"prior":[182,409,438,444,625,635],"lenalidomide,":[183],"must":[185],"relapsed":[187],"were":[189,265,283,313,382,403,448,565],"their":[192,278,667],"most":[193],"recent":[194],"na\u00efve.":[206],"Treatment":[207],"consisted":[208],"28-day":[210],"cycles":[211,480],"oral":[213,236],"once":[215],"daily":[216],"days":[218,227,243,258],"1-21,":[219],"intravenous":[220],"(IV)":[221],"over":[223],"30":[224,346],"minutes":[225],"1,":[228,244,257],"2,":[229],"8,":[230,245],"9,":[231],"15,":[232,246,392],"16,":[234],"IV":[238],"40":[240,330,357],"22":[248],"initiated":[251],"at":[252,260,273,340],"20":[253,338],"mg/m2":[254],"Cycle":[256],"1-2":[259],"all":[261,447],"dose":[262,270,322],"levels.":[263],"Investigators":[264],"permitted":[266],"adjust":[268],"any":[274],"point":[275],"discretion.":[279],"Adverse":[280],"events":[281],"(AEs)":[282],"graded":[284],"by":[285,291],"NCI-CTCAE":[286],"v4.":[287],"Response":[288,296],"assessed":[290],"modified":[293],"International":[294],"Uniform":[295],"Criteria.":[297],"Results":[298],"I":[302],"total":[309,344,365],"12":[311],"enrolled.":[314],"established":[318],"starting":[321],"level":[323],"(carfilzomib":[324],"20/27":[325],"mg/m2,":[326],"4mg,":[328],"mg).":[331],"enrolled":[333,356],"toxicity-evaluable":[347],"8":[350],"centers.":[351],"82":[359],"planned":[360],"resulting":[362],"study":[366],"population":[367,623],"72":[369,381,500],"patients,":[370],"29":[372],"still":[373],"receiving":[374],"treatment.":[375],"Five":[376],"out":[378,498],"not":[383],"yet":[384],"evaluable":[385],"efficacy.":[387],"Data":[388],"cut-off":[389],"June":[391],"2013.":[393],"median":[395,406,415,423,477,586,630],"age":[396],"64":[398],"years":[399,421],"(range":[400,413,481],"41\u201378),":[401],"63%":[402],"male.":[404],"number":[407],"regimens":[410],"6":[412,457,488,632],"2\u201315),":[414],"diagnosis":[418],"5.1":[420],"follow-up":[424],"6.0":[426],"months":[427,590],"(range:":[428],".5":[429],"16.1":[431],"months).":[432],"Two-thirds":[433],"stem":[439],"cell":[440],"transplant,":[441],"87%":[442],"bortezomib,":[445],"lenalidomide-refractory.":[449],"Cytogenetic":[450],"abnormalities":[451],"16":[453],"del(17p),":[456],"t(4;14),":[460],"23,":[462],"14,":[463],"5":[465,479],"each":[467],"del(13),":[469],"t(11;14),":[470],"t(14;16),":[472],"respectively.":[473],"Patients":[474,575],"received":[475],"1\u201318":[482],"cycles).":[483],"Ten":[484],"died,":[487],"progressive":[490],"myeloma.":[492],"Best":[493],"assessments":[495],"67":[497],"showed":[502],"1":[503],"CR,":[504],"18":[505],"VGPR,":[506],"24":[507],"PR,":[508],"11":[509,511],"MR,":[510],"SD,":[512],"2":[514],"PD":[515],"ORR":[518],"64%":[520],"\u2265MR":[523,593,614],"81%.":[526],"Grade":[527],"\u22653":[528,554],"drug-related":[529],"AEs":[530,555],">20%":[533],"fatigue":[537],"(48%),":[538],"neutropenia":[539],"(40%),":[540],"anemia":[541],"(34%),":[542,544],"thrombocytopenia":[543],"diarrhea":[546],"(20%).":[547],"Sixty-two":[548],"percent":[549],"experienced":[552],"grade":[553],"neutropenia,":[557],"anemia,":[558],"diarrhea.":[560],"Median":[561],"PFS":[562,587],"OS":[564],"12.0":[566],"16.3":[568],"months,":[569],"respectively,":[570],"entire":[573],"cohort.":[574],"intermediate-":[577],"high-risk":[579],"cytogenetics":[580],"(mSMART":[581],"criteria,":[582],"N=33)":[583],"9.6":[589],"84%.":[596],"Conclusions":[597],"is":[601],"well-tolerated":[603],"achieves":[606],"(ORR":[611],"64%;":[613],"81%)":[617],"heavily":[620],"pre-treated":[621],"Lenalidomide-refractory":[622],"exposure,":[627],"lines":[633],"Importantly,":[637],"seen":[640],"responses":[641],"poor":[645],"risk":[646],"cytogenetics,":[647],"specifically":[648],"del":[649],"(17p)":[650],"prolonged":[652],"disease":[653],"control.":[654],"like":[657],"acknowledge":[659],"Onyx":[660,703],"Pharmaceuticals,":[661,842],"Inc.":[662],"Celgene":[664],"Corporation":[665],"support":[668],"study.":[671],"Disclosures:":[672],"Shah:":[673],"Novartis:":[674,822],"Honoraria,":[675,690,705,719,724,746,750,754,764,780,855,869,887,901,919,931],"Membership":[676,691,706,725,768,784,795,808,856,870,888,902,920,932,943],"entity\u2019s":[679,694,709,728,771,787,798,811,859,873,891,905,923,935,946],"Board":[680,695,710,729,772,788,799,812,860,874,892,906,924,936,947],"Directors":[682,697,712,731,774,790,801,814,862,876,894,908,926,938,949],"advisory":[684,699,714,733,776,792,803,816,864,878,896,910,928,940,951],"committees,":[685,700,715,734,804,817,865,879,897,911],"Research":[686,701,716,720,735,747,751,755,765,781,824,828,836,839,844,847,866,880,898,912,915],"Funding;":[687,702,717,721,748,752,766,825,829,845,848,867,881,899,913,916],"Array":[688,917],"BioPharma:":[689],"Pharmaceuticals:":[704,723,831],"Celgene:":[718,753,767,794,826,849,868],"Millennium":[722,830],"Funding.":[736,756,782,837,840],"Stadtmauer:Celgene:":[737],"Consultancy,":[738,742,779,823,827],"Speakers":[739,743,805,818],"Bureau;":[740,806],"Millenium:":[741],"Bureau.":[744,819],"Abonour:Onyx:":[745],"Millennium:":[749,807,846,882,957],"Cohen:Millennium:":[757],"Honoraria;":[758,760],"Onyx:":[759,900,955],"Bristol":[761],"Myers":[762],"Squibb:":[763,854],"committees.":[777,952],"Bensinger:Celgene:":[778],"Gasparetto:Onyx:":[783],"committees;":[793,929,941],"Kaufman:Onyx:":[820],"Consultancy;":[821,832,834,850,954,956,958],"Jansenn:":[833],"Merck:":[835,942],"Lentzsch:Celgene:":[838],"Vogl:Acetylon":[841],"Inc:":[843],"Otsuka:":[851],"Consultancy.":[852,960],"Orlowski:Bristol-Myers":[853],"Takeda":[884],"Oncology":[885],"Company:":[886],"Resverlogix:":[914],"Biopharma:":[918],"Genentech:":[930],"Durie:Celgene:":[953],"Amgen:":[959]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":12}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}